598 related articles for article (PubMed ID: 31319795)
1. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
2. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
[TBL] [Abstract][Full Text] [Related]
5. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
6. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
9. Do associated auto-antibodies influence the outcome of myasthenia gravis after thymectomy?
Keijzers M; Damoiseaux J; Vigneron A; Bodart N; Kessels A; Dingemans AM; Hochstenbag M; Maessen J; De Baets M
Autoimmunity; 2015; 48(8):552-5. PubMed ID: 26226195
[TBL] [Abstract][Full Text] [Related]
10. Early-onset myasthenia gravis.
Roach ES; Buono G; McLean WT; Weaver RG
J Pediatr; 1986 Feb; 108(2):193-7. PubMed ID: 3944702
[TBL] [Abstract][Full Text] [Related]
11. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.
Niks EH; Kuks JB; Verschuuren JJ
J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):417-8. PubMed ID: 17056627
[TBL] [Abstract][Full Text] [Related]
13. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy.
Heng HS; Lim M; Absoud M; Austin C; Clarke D; Wraige E; Reid C; Robb SA; Jungbluth H
Neuromuscul Disord; 2014 Jan; 24(1):25-30. PubMed ID: 24239058
[TBL] [Abstract][Full Text] [Related]
14. Juvenile myasthenia gravis with prepubertal onset.
Evoli A; Batocchi AP; Bartoccioni E; Lino MM; Minisci C; Tonali P
Neuromuscul Disord; 1998 Dec; 8(8):561-7. PubMed ID: 10093062
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholine receptor antibodies in juvenile myasthenia gravis.
Andrews PI; Massey JM; Sanders DB
Neurology; 1993 May; 43(5):977-82. PubMed ID: 8492956
[TBL] [Abstract][Full Text] [Related]
16. Three cases of myasthenia gravis from one family with variations in clinical features and serum antibodies.
Chen Y; Wang W; Wei D; Yang L
Neuromuscul Disord; 2012 Mar; 22(3):286-8. PubMed ID: 22082588
[TBL] [Abstract][Full Text] [Related]
17. Paediatric myasthenia gravis: Prognostic factors for drug free remission.
Vecchio D; Ramdas S; Munot P; Pitt M; Beeson D; Knight R; Rodríguez Cruz P; Vincent A; Jayawant S; DeVile C; Buckley C; Hilton-Jones D; Robb S; Palace J
Neuromuscul Disord; 2020 Feb; 30(2):120-127. PubMed ID: 32001147
[TBL] [Abstract][Full Text] [Related]
18. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years.
Anlar B; Senbil N; Köse G; Değerliyurt A
Neuromuscul Disord; 2005 May; 15(5):355-7. PubMed ID: 15833428
[TBL] [Abstract][Full Text] [Related]
19. [Myasthenia gravis. Register of 190 cases in a single center].
Aguirre F; Villa AM
Medicina (B Aires); 2020; 80(1):10-16. PubMed ID: 32044736
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
